Finanzen von Edgewise Therapeutics Inc (EWTX)EWTXEdgewise Therapeutics Inc

Evaluating the bottom line, Edgewise Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -38.03%, provide a clear picture of how effectively EWTX converts its operational activities into shareholder value.

In the context of the broader market, EWTX competes directly with industry leaders such as DNTH and ADPT. With a market capitalization of $4.04B, it holds a significant position in the sector. When comparing efficiency, EWTX's gross margin of N/A stands against DNTH's 100.00% and ADPT's 71.23%. Such benchmarking helps identify whether Edgewise Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has reported negative net income for several quarters, with the latest being -$57.3 million in Q2 2026. The current ratio remains high at 16.24, indicating good liquidity, but the overall financial performance shows significant losses.